

HEALTHCARE INDUSTRY Q4 2024 VALUATION UPDATE





## Table of Content

Industry Overview

**Global Comparable Public Companies** 

**Global Transactions** 

**About Seale** 





# Introduction

We are pleased to share our Healthcare Industry Multiples Valuation Update for Q4 2024.

At Seale & Associates, we are committed to providing process-driven solutions designed to optimize value and achieve our client's strategic objectives in a range of transactions, including Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures, among other corporate finance and strategy consulting services.

Over the course of 25+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our clients who are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms, and family-owned businesses across a wide range of industries.



James A. Seale | President jseale@sealeassociates.com



**Brett M. Carmel | Senior Managing Director** bcarmel@sealeassociates.com



**Robert Whitney | Managing Director** rwhitney@sealeassociates.com



Sergio Garcia del Bosque | Managing Director sgarcia@sealeassociates.com



**Carlos Hernández Goudet | Managing Director** chernandez@sealeassociates.com





Alejandro Montemayor | Vice President amontemayor@sealeassociates.com

Armando Rios | Vice President arios@sealeassociates.com



## Healthcare's Industry Overview, M&A Trends and Market Intelligence

#### Healthcare M&A Trends and Market Intelligence


- 2024 was largely a year of stabilization for health systems, despite ongoing economic uncertainty, intensifying natural disasters, and continued geopolitical tensions. As we approach 2025, early signs of a more favorable interest rate environment are beginning to emerge, offering optimism for the sector
- **M&A activity** remained **strong** in Q4 2024, with 784 transactions completed. Although this marks a slight decline from earlier in the year, deal momentum remained steady. High average deal values indicate that larger, strategic transactions continue to drive the market
- **Private equity** remained a **key player**, accounting for 128 announced healthcare deals in Q4. While this figure was **down from the previous quarter**, the presence of several US\$1.0B+ transactions underscores continued investor confidence and interest in the sector
- Demographic shifts, particularly the growing elderly population, have driven a 5.6% increase in inpatient volumes and a 5.9% rise in average lengths of stay over the past decade. This sustained demand is shaping both strategic planning and M&A activity across the industry
- **Technological innovation**, **especially** in **artificial intelligence (AI)**, continues to transform healthcare delivery and operations. Venture capital interest in Aldriven healthtech startups is gaining momentum, with a focus on driving operational efficiency and reigniting sector investment
- Looking ahead, outpatient care is expected to accelerate. Over the next ten years, ambulatory surgical center volumes are projected to grow by 18.0%, medical office buildings by 21.0%, and hospital-based outpatient services by 15.0%. This shift will likely be supported by initiatives aimed at steering patients toward ambulatory settings
- Alternative funding models such as physician-backed ASCs and private equityowned healthcare real estate are expected to proliferate. Additionally, market consolidation will remain active, as providers pursue strategic M&A to gain scale and strengthen their competitive positions

Source: Capital IQ, Wall Street Journal, DPR Construction, and other Industry Reports

#### Healthcare Industry M&A Deal Size and Volume



Healthcare Industry M&A Average EV/EBITDA and EV/Revenue





## Pharmaceutical Producers Global Comparable Public Companies (1/3)

		Market	Enterprise	Revenue	EBITDA	Annual A EV/EBI			Quarter 1, 2024
Company	Country	Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	EV/ Revenue
AbbVie Inc.	abbvie USA	\$314,021	\$378,098	\$56,334	46.0%	11.2x	10.5x	14.6x	6.7x
Astellas Pharma Inc.	🗡 astellas JPN	\$17,470	\$21,559	\$11,878	19.5%	11.0x	10.3x	9.3x	1.8x
AstraZeneca PLC	AstraZeneca GBR	\$203,171	\$228,175	\$54,073	34.5%	21.7x	14.7x	12.2x	4.2x
Bausch Health Companies Inc.	<b>BAUSCH</b> Health CAN	\$2,964	\$24,684	\$9,625	32.7%	8.3x	8.4x	7.8x	2.6x
Bristol-Myers Squibb Company	USA USA	\$114,714	\$157,791	\$48,300	40.7%	8.9x	8.3x	8.0x	3.3x
Daiichi Sankyo Company, Limited	Daiichi-Sankyo JPN	\$52,135	\$48,280	\$11,422	20.5%	46.8x	48.6x	20.6x	4.2x
Eisai Co., Ltd.	<b>Eisai</b> JPN	\$7,761	\$7,370	\$5,035	10.2%	37.5x	49.5x	14.4x	1.5x













## Pharmaceutical Producers Global Comparable Public Companies (2/3)

			Market	Enterprise Value	Revenue	EBITDA	Annual EV/EE	Average BITDA	Fourth Qua Dec. 31, 20	
Company	C	ountry	Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E' Reve
GSK plc	gsk	GBR	\$68,786	\$84,174	\$39,280	30.1%	8.8x	7.3x	7.1x	2.
Johnson & Johnson	Johnson-Johnson	USA	\$348,190	\$363,644	\$88,821	34.1%	14.0x	12.6x	12.0x	4.
Merck & Co., Inc.		USA	\$251,648	\$275,244	\$64,168	36.3%	11.1x	12.6x	11.8x	4.
Novartis AG	<b>U</b> NOVARTIS	CHE	\$195,695	\$212,877	\$51,722	41.0%	6.2x	10.5x	10.0x	4.
Novo Nordisk A/S	novo nordisk <sup>®</sup>	DNK	\$384,849	\$382,362	\$40,314	46.3%	25.1x	29.3x	20.5x	9.
Otsuka Holdings Co., Ltd.	Otsuka	JPN	\$29,377	\$28,529	\$14,818	23.1%	9.4x	7.9x	8.3x	1.9
Pfizer Inc.	<b>Pfizer</b>	USA	\$150,345	\$208,609	\$63,627	31.3%	7.6x	6.3x	10.5x	3.



















## Pharmaceutical Producers Global Comparable Public Companies (3/3)

Company	Co	ountry	Market	Enterprise Value	Revenue	EBITDA		Average BITDA	Fourth Dec. 3	
Company	CO	Junity	Cap. US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Reve
Roche Holding AG	Roche	CHE	\$226,434	\$260,969	\$68,855	34.2%	12.1x	9.8x	11.1x	3.
Sanofi	sanofi	FRA	\$121,097	\$138,969	\$45,849	28.7%	10.5x	9.1x	10.5x	3.
Shionogi & Co., Ltd.	SHIONOGI	JPN	\$12,006	\$10,265	\$2,906	36.3%	19.7x	8.5x	9.7x	3.
Sun Pharmaceutical Industries Limited	<b>SUN</b> PHARMA	IND	\$52,909	\$50,888	\$6,032	27.0%	20.6x	21.5x	31.3x	8.
Takeda Pharmaceutical Company Limited	Takeda	JPN	\$42,152	\$72,370	\$29,123	30.2%	8.6x	9.4x	8.2x	2.
Teva Pharmaceutical Industries Limited	teva	ISR	\$25,006	\$41,281	\$16,544	29.7%	7.0x	7.4x	8.4x	2.
UCB SA	urb	BEL	\$37,751	\$40,453	\$6,369	19.3%	11.2x	14.1x	33.0x	6.
Excluded from mean and median						Mean	10.3x	9.9x	10.2x	3.
						Median	11.1x	10.3x	10.5x	3.

















## Medical Devices & Consumables Global Comparable Public Companies (1/2)

Company	Cou			terprise Value	Revenue	EBITDA	Annual Av EV/EBI1		Fourth Dec. 3	Ŭ
Company		ountry Cap. US\$M		US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E' Reve
Ansell Limited	Ansell A	US \$3	,028	\$2,991	\$1,854	14.3%	8.0x	8.8x	11.3x	1.6
Baxter International Inc.	<b>Baxter</b> L	JSA \$14	,889 \$	526,733	\$10,636	27.8%	14.8x	10.8x	9.0x	2.
Becton, Dickinson and Company	Solution BD	JSA \$65	5,794 \$	584,551	\$20,640	25.9%	16.1x	17.7x	15.8x	4.
Boston Scientific Corporation	Scientific L	JSA \$13	1,642 \$1	140,646	\$16,747	24.9%	20.9x	24.4x	33.8x	8.
Cardinal Health, Inc.	CardinalHealth <sup>™</sup>	JSA \$28	3,623 \$	530,921	\$222,276	1.4%	7.8x	9.2x	10.1x	0.
ConvaTec Group PLC	Seconvatec G	BR \$5	,668	\$6,970	\$2,289	21.7%	15.8x	15.2x	14.1x	3.0
Edwards Lifesciences Corporation	E Edwards Lifesciences	JSA \$4	3,663 \$	39,982	\$5,440	38.3%	32.9x	25.2x	19.2x	7.
Hogy Medical Co.,Ltd.	HOGY. J	PN \$	651	\$601	\$250	25.0%	7.3x	6.7x	9.6x	2.4





















## Medical Devices & Consumables Global Comparable Public Companies (2/2)

	Countr	Market	Enterprise	Revenue	EBITDA		l Average EBITDA	Fourth Dec. 3	Quart 31, 2024
Company	Countr	y Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Reve
ICU Medical, Inc.	icumedical USA	\$3,799	\$5,134	\$2,382	12.3%	21.5x	18.4x	17.5x	2.
West Pharmaceutical Services, Inc.	West 🔶 USA	\$23,723	\$23,540	\$2,893	27.3%	25.0x	27.8x	29.8x	8.
JMS Co.,Ltd.	JPN	\$68	\$176	\$445	6.1%	6.2x	6.8x	6.5x	0.
Medtronic plc	<b>Medtronic</b> IRL	\$102,429	\$122,954	\$32,996	28.6%	14.5x	14.4x	13.0x	3.
Merit Medical Systems, Inc.	USA MERITAEDICAL USA	\$5,637	\$5,933	\$1,357	19.5%	18.0x	21.4x	22.4x	4.
Owens & Minor, Inc.	Owens & Minor USA	\$1,008	\$3,135	\$10,701	7.3%	8.5x	7.6x	4.0x	0.
Stryker Corporation	<b>stryker</b> USA	\$137,257	\$148,580	\$22,595	26.0%	21.2x	25.0x	25.3x	6.
Teleflex Incorporated	Global Knowledge Network	\$8,266	\$9,919	\$3,047	22.2%	17.3x	15.3x	14.7x	3.
Excluded from mean and median					Mean	14.8x	15.1x	13.7x	3.
					Median	15.9x	15.2x	14.4x	3.






















## Drug Stores Global Comparable Public Companies

Company		Country	Market Cap.	Enterprise Value	Revenue	EBITDA		Average BITDA	Fourth Dec. 3	Quart 31, 2024
Company		country	US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev
Corporativo Fragua, S.A.B. de C.V.	FRAGUA	MEX	\$3,215	\$3,118	\$5,649	5.4%	6.8x	7.8x	10.3x	0
CVS Health Corporation	♦ CVS Health.	USA	\$56,490	\$129,676	\$370,656	4.7%	8.8x	7.0x	7.5x	0
Dimed S.A. Distribuidora de Medicamentos	DIMED	BRA	\$213	\$365	\$779	5.3%	11.6x	10.0x	8.9x	0
Empreendimentos Pague Menos S.A.	Pague Menos	BRA	\$294	\$837	\$2,044	5.8%	7.9x	7.5x	7.0x	0.
Farmacias Benavides, S.A.B. de C.V.	benävides	MEX	\$432	\$596	\$849	10.7%	4.5x	4.8x	6.6x	0
Raia Drogasil S.A.	RaiaDrogasil S.A.	BRA	\$6,101	\$7,260	\$6,284	10.2%	15.3x	15.4x	11.3x	٦.
Walgreens Boots Alliance, Inc.	Walgreens Boots Alliance	USA	\$8,056	\$40,529	\$150,410	4.9%	7.9x	9.5x	5.5x	0
Excluded from mean and median						Mean	7.9x	7.8x	7.6x	0.
						Median	7.9x	7.8x	7.5×	0.









0.5x







0.3x



## Pharmaceutical Products - Q4 Global Transactions (1/2)

Date	Target	Country	Description
Dec-24	MARINUS PHARMACEUTICALS	USA	<b>Immedica Pharma</b> , rare disease company, acquired <b>Marinus Pha</b> developer of therapeutics for seizure disorders, adding ZTALMY® ( portfolio
Dec-24 <sup>*</sup>	IKENA	USA	<b>Inmagene</b> , biotechnology company, agreed to merge with <b>Ikena</b> ( therapies targeting cancer growth and resistance, focusing on dev antibody for treating atopic dermatitis
Dec-24		CAN	LSL Pharma Group, pharmaceutical company, acquired Dermolal manufacturer specializing in liquid and semi-solid products
Dec-24 <sup>*</sup>	Synthon	NLD	<b>Goldman Sachs Asset Management</b> , investment management fir majority stake in <b>Synthon</b> , provider of complex generics, from BC F retain a minority stake
Dec-24	VISUS	USA	<b>Tenpoint Therapeutics</b> , provider of pharmaceuticals for rejuvenate eye, merged with <b>Visus Therapeutics</b> , provider of ophthalmic there the Next Era of Best- and First-in-Class Ophthalmic Medicines
Dec-24	Pulmokine	USA	<b>XOMA Royalty</b> , biotechnology royalty aggregator, acquired <b>Pulmo</b> therapies for pulmonary arterial hypertension (PAH), to add seralu to its portfolio
Nov-24	Carragelose Business of Marinomed	AUT	Unither Pharmaceuticals, manufacturer of medical devices and p products acquired the Carragelose business of Marinomed, biop company specializing in respiratory diseases
Nov-24 <sup>*</sup>	Gujarat Themis Biosyn Limited	IND	<b>Themis Medicare</b> , manufacturer of finished formulations and synt pharmaceutical ingredients (APIs), agreed to merge with <b>Gujarat</b> <b>Limited</b> , producer of fermentation-based pharmaceutical interme
Nov-24 <sup>*</sup>	Assets of Neurelis	USA	OrbiMed, healthcare investment firm, agreed to acquire Neurelis's interests in neffy® (nasal epinephrine) which comprises therapie candidates for epilepsy, psychiatry, and the central nervous system
Nov-24 <sup>*</sup>	New Entity: Cullgen Inc.	USA	<b>Cullgen</b> , biopharmaceutical company, agreed to merge with <b>Pulm</b> biopharmaceutical company developing inhaled therapies for resp creating a Nasdaq-listed entity

Source: Capital IQ, Companies' Press Releases, Mergermarket

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	R
a <b>rmaceuticals</b> , (ganaxolone) to its		-	100.0%	\$126.3	-	
<b>a Oncology</b> , developer of eveloping IMG-007,		-	Merger	\$86.5	-	
<b>ab Pharma</b> , contract	PHARMA GROUP TSXV: LSL	-	100.0%	\$2.8	7.9x	
firm, agreed to acquire a C Partners , which will	Goldman Sachs Asset Management	BC PARTNERS	>50.0%	-	-	
ating vision in the aging erapies, aiming to build	tenpoint THERAPEUTICS	-	Merger	-	-	
<b>nokine</b> , provider of Iutinib, a Phase 3 asset,		-	100.0%	\$20.0	-	
pharmaceutical pharmaceutical		Marinomed	100.0%	\$20.9	-	
nthetic active <b>t Themis Biosyn</b> nediates and APIs	THEMIS M E D I C A R E	-	Merger	\$319.1	-	
<b>s's rights and royalty</b> bies and product em market	orbimed	NEURELIS	100.0%	\$208.0	_	
<b>lmatrix</b> , espiratory diseases,	cullgen	PULMATRIX	Merger	\$280.0	-	









-

## Pharmaceutical Products – Q4 Global Transactions (2/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Nov-24	Bio 🕏 Convert	DNK	<b>Nordicus</b> , consulting firm specializing in assisting life sciences companies in entering the U.S. market, acquired <b>Bio-Convert</b> , biopharmaceutical company focused on developing treatments for oral leukoplakia	N O R D I C <b>U S</b>	-	100.0%	\$60.6	-	
Nov-24	htba	ESP	<b>Miura Partners</b> in partnership with <b>Evolve HealthCare Partners</b> , private equity firms, acquired HealthTech BioActives (HTBA), manufacturer of flavonoids and active forms of vitamin B12	Miura Partners Construction Free Partners Provide HealthCare Partners SHAPING THE INDUSTRY TOGETHER	-	100.0%	-	-	
Nov-24 <sup>*</sup>	Manufacturing Facility and Reagent Supply Business	USA	Ampersand, private equity firm, agreed to acquire manufacturing facility and reagent supply business of Nektar, establishing Gannet BioChem	& Ampersand	<b>NEKTAR</b> <sup>°</sup>	100.0%	\$90.0	-	
Oct-24 <sup>*</sup>	<b>PYROS</b> ™	USA	<b>Bora Pharmaceuticals</b> , pharmaceutical company, agreed to acquire <b>Pyros</b> , developer of pharmaceuticals for rare dseases, enhacing its portfolio with VIGAFYDE™, oral solution for infantile spasms	Bora bora Pharmaceuticals	-	100.0%	\$54.9	-	
Oct-24 <sup>*</sup>	<b>FAIRMED</b> <sup>®</sup> Healthcare Group Switzerland	CHE	<b>Strides</b> , manufacturer of pharmaceutical products, over-the-counter drugs and nutraceuticals, agreed to acquire a 70% stake in <b>Fairmed Healthcare</b> , provider of generic prescription and over-the-counter drugs	Strides 8	-	70.0%	\$2.5	-	
Oct-24 <sup>*</sup>	PAEDIPROTECT	DEU	<b>NanoRepro AG</b> , manufacturer and distributor of rapid diagnostic tests and nutritional supplements, agreed to acquire an additional 50% stake in <b>Paedi Protect</b> , provider of skincare products	Nano Repro NanoRepro AG	-	50.0%	\$18.7	-	
Oct-24	LONGBOARD PHARMACEUTICALS	USA	<b>Lundbeck</b> , provider of pharmaceutical products, acquired <b>Longboard Pharmaceuticals</b> , biopharmaceutical company focused on neurological diseases, through its wholly owned subsidiary, Langkawi Corporation	Lundbeck	-	100.0%	\$2,653.2	-	
Oct-24	Global Rights to Enjaymo	FRA	<b>Recordati</b> , provider of pharmaceutical products, acquired the <b>global rights to</b> <b>Enjaymo</b> ® (sutimlimab) from Sanofi, adding the only approved treatment for cold agglutinin disease (CAD)	RECORDATI	sanofi	100.0%	\$825.0	-	
Oct-24	Increlex®	USA	<b>Eton Pharmaceuticals</b> , pharmaceutical company, acquired <b>Increlex®</b> (mecasermin injection) from Ipsen S.A., acquiring the only FDA- and EMA-approved treatment for severe primary growth factor 1 deficiency		<b>IPSEN</b> Innovation for patient care	100.0%	\$22.5	-	
*Annound ND: Not D	ed transactions pending a Disclosed	pproval an	d other closing conditions				Mean Median	7.9x 7.9x	

Source: Capital IQ, Companies' Press Releases, Mergermarket









8.3x

2.9x

1.5x

## Medical Equipment – Q4 Global Transactions (1/2)

Date	Target	Country	Description
Dec-24	Carle Medical Supply	USA	<b>Medical Service Company</b> , provider of medical equipment and reacquired <b>Carle Medical Supply</b> , provider of medical equipment and Health, enhacing its patient care and discharge processes
Dec-24	Blood Collection, Processing, and Filtration Portfolio	USA	<b>GVS</b> , manufacturer of advanced filtration solutions, acquired the <b>b processing, and filtration solutions portfolio from Haemonetics</b> enhancing its presence in transfusion medicine
Dec-24 <sup>*</sup>	MEDIEIL GEM	IRL/ITA	<b>H.B. Fuller</b> , provider of pureplay adhesives, agreed to acquire <b>Med</b> manufacturers of medical devices, enhancing its Medical Adhesive business
Nov-24 <sup>*</sup>		USA	<b>Boston Scientific</b> , provider of medical technology, agreed to acqu provider of medical devices specialized in the Intera 3000 Hepatic and floxuridine
Nov-24	MEBXL	CAN	<b>Amsino</b> , manufacturer of medical devices, acquired the <b>MedXL</b> , p syringes for intravenous drug therapy, expanding its North Americ footprint
Nov-24	<b>M</b> fortimedix surgical	NLD	<b>Medtronic</b> , provider of medical technology, acquired <b>Fortimedix S</b> flexible articulating instruments for endoscopic and minimally inv enhancing its surgical and endoscopy portfolio
Nov-24	Schivo	IRL	<b>Five Arrows Managers</b> , the alternative assets arm of Rothschild & manufactirer of high-precision engineering for the robotic-assisted invasive surgery, and life sciences sectors
Nov-24		FRA	Halma, group of life-saving technology companies, acquired Lami manufacturer of advanced electrosurgical and associated energy of
Nov-24 <sup>*</sup>	cortex	USA	<b>Boston Scientific</b> , provider of medical technology, agreed to acqu medical technology known for its Cortex's OptiMap <sup>™</sup> System, from enhancing its electrophysiology portfolio
Nov-24	Clareblend, Inc. "Making A Difference"	USA	<b>Silhouet-Tone</b> , manufacturer of high-quality equipment, acquired producer of electrology and microcurrent devices for the medspaindustries, enhacing its product offerings

Source: Capital IQ, Companies' Press Releases, Mergermarket

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	R
respiratory services, and services, from Carle	Medical Service Company	<b>Carle</b> Health	100.0%	-	-	
blood collection, cs Corporation,	GVS	<b>HAEMONETICS</b> <sup>®</sup>	100.0%	\$45.3	-	
<b>difill and GEM</b> , ve Technologies	<b>H.B.</b> Fuller	-	100.0%	\$180.0	15.5x	
uire <b>Intera Oncology</b> , c Artery Infusion Pump	Boston Scientific Advancing science for life™	-	100.0%	-	-	
producer of prefilled rican manufacturing	AMSINO Advancing Healthcare Worldwide*	-	100.0%	-	-	
<b>CSurgical</b> , provider of Invasive surgeries,	Medtronic	-	100.0%	-	-	
& Co, acquired <b>Schivo</b> , ed surgery, minimally	Five Arrows Rothschild & Co	-	100.0%	-	-	
<b>nidey Noury Medical</b> , y devices	<b>Q</b> Halma	-	100.0%	\$52.8	-	
juire <b>Cortex</b> , provider of om Ajax Health,	Boston Scientific Advancing science for life™	AJAX	100.0%	-	-	
ed <b>Clareblend, Inc.</b> , a and skincare	Silhouet-Tone	-	100.0%	-	-	























## Medical Equipment – Q4 Global Transactions (2/2)

Date	Target	Country	Description
Nov-24	NUÂRE	USA	<b>Kewaunee</b> , provider of laboratory furniture and technical product manufacturer of biological safety cabinets, airflow products, CO <sub>2</sub> in freezers, and related equipment
Oct-24	arthrosurface®	USA	<b>Phoenix Brio, Inc.</b> , manufacturer and commercializer of therapeur <b>Arthrosurface</b> , provider of joint restoration and preservation solut enhacing its orthopedic offerings
Oct-24	Joerns Oxford® aprismhealthcare company	GBR	<b>Prism Healthcare</b> , provider of safe patient handling and rehabilitation acquired <b>Joerns Healthcare's UK business</b> , including the 'Oxford' hoisting equipment, slings, and bathing products
Oct-24	Member of REINSBERG' GROUP	GBR	<b>Reinsberg Group</b> , MedTech holding of BHM group, acquired a ma <b>Medical</b> , manufacturer of medical equipment, aiming to build a st independent European medical manufacturers
Oct-24	<b>SENSIBLE</b> DIAGNOSTICS	USA	Access Genetics dba OralDNA® Labs, provider of DNA testing an acquired Sensible Diagnostics, developer of molecular diagnostic commercialize new molecular diagnostics
Oct-24	CARDIOMED DEVICE CONSULTANTS	USA	<b>Tentamus</b> , provider of analytical and quality assurance services, ac <b>Device Consultants</b> , consulting firm specializing in cardiovascular enhacing its service offerings
Oct-24	SUMEd®	GBR	<b>DHG</b> , manufacturer of medical devices, acquired <b>Sumed</b> , manufacturer of medical devices, acquired <b>Sume</b> , acquired <b>Sum</b> , a
Oct-24	gynesuncs	USA	Hologic, provider of women's health solutions, acquired <b>Gynesoni</b> devices focused on the development of minimally invasive solution increase access to their Sonata® System
Oct-24	Rehabilitation business of Bioness	USA	Accelmed, private equity firm, acquired the Advanced Rehabilita Bioness, subsidiary of Bioventus provider of rehabilitation product portfolio in neuromuscular rehabilitation technologies

\*Announced transactions pending approval and other closing conditions

ND: Not Disclosed

Source: Capital IQ, Companies' Press Releases, Mergermarket

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	R
cts, acquired <b>NuAire</b> , incubators, ultralow	KEWAUNEE	-	100.0%	\$55.0	-	
eutic products, acquired utions for active patients,	Phoenix Brio, Inc.	<b>Ξ</b> ΑΝΙΚΑ	100.0%	-	-	
itation products, d' range of clinical	prism <b>healthcare</b>	<b>Joerns</b> <sup>®</sup> HEALTHCARE	100.0%	-	-	
najority stake in <b>Brandon</b> strong group of	REINSBERG <sup>®</sup> GROUP	-	>50.0%	-	_	
and salivary diagnostics, tic equipment, aiming to	access genetics	-	100.0%	-	-	
acquired <b>CardioMed</b> ar medical devices,	Tentamus <sup>®</sup> Labs for Life	-	100.0%	-	-	
acturer of medical ure ulcer prevention	<b>DHG</b> Moving Health Forward	-	100.0%	-	-	
<b>nics</b> , provider of medical ons for women's health,	HOLOGIC	-	100.0%	\$350.0	-	
tation business of acts, enhancing its	Accelmed	Bioness bioventus	100.0%	\$25.0	-	
				Mean	15.5x	
				Median	15.5x	



















3.7x

## Hospitals - Q4 Global Transactions (1/2)

	-	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Dec-24	OrthoAlliance <sup>®</sup>	USA	<b>SCA Health</b> , ambulatory surgery center (ASC) division of Optum, acquired <b>OrthoAlliance</b> , orthopedic management services organization with over 200 physician partners	<b>SCA</b> Health	_	100.0%	\$1,400.0	-	
Dec-24	<b>RG</b> Hospitals	IND	<b>Morgan Stanley Private Equity Asia</b> , through its fund NHPEA V Star (BVI) Limited, acquired a 85% stake in <b>R.G. Hospitals</b> , chain specializing in urological and laparoscopic healthcare services	NHPEA V Star (BVI) Limited, Morgan Stanley Private Equity	-	85.0%	-	-	
Dec-24	Spital Zofingen AG	CHE	<b>Swiss Medical Network</b> , private hospital group, acquired <b>Spital Zofingen AG</b> , operator of an acute hospital and a care center, from Kantonsspital Aarau AG (KSA)	SWISS MEDICAL NETWORK	KSA Kantonsspital Aarau	100.0%	\$551.2	13.9x	
Dec-24	Southern Indiana Rehabilitation Hospital	USA	<b>PAM Health</b> , healthcare provider specializing in post-acute care, acquired <b>Southern</b> <b>Indiana Rehabilitation Hospital</b> , provider of specialized care for patients recovering from debilitating illnesses and injuries	PAM HEALTH	-	100.0%	-	-	
Dec-24	Center for Social Dynamics	USA	<b>Goldman Sachs Alternatives</b> , investment firm, acquired <b>CSD</b> , provider of applied behavior analysis for children with autism, from NMS Capital, which will reinvest in CSD alongside Goldman Sachs	Goldman Asset   Management CAPITAL	NMS   CAPITAL	ND	-	-	
Nov-24 <sup>*</sup>	CARE HOSPITALS	IND	<b>Aster</b> , provider of healthcare services, agreed to merge with <b>Quality Care India Limited</b> , Blackstone and TPG-backed hospital chain, forming Aster DM Quality Care Limited, creating one of India's top three hospital chains with 38 hospitals	Aster We'll Treat You Well	CARE	Merger	\$107.5	-	
Nov-24 <sup>*</sup>	Bayonne Medical Center	USA	Hudson Regional Hospital, provider of healthcare services, agreed to acquire Bayonne Medical Center, 278-bed hospital	HUDSON REGIONAL HOSPITAL	-	100.0%	-	-	
Nov-24	RIGHT CARE. RIGHT PRICE. RIGHT NOW.	USA	<b>Great Hill Partners</b> , private equity firm, acquired <b>Intuitive Health</b> , operator of freestanding hybrid emergency department and urgent care centers	Great Hill PARTNERS	Altamont A	>50.0%	-	-	
Nov-24	Lehigh Regional Medical Center	USA	HCA Florida Healthcare, provider of health systems, acquired Lehigh Regional Medical Center, 53-bed hospital, from Prime Healthcare	HCA Florida Healthcare	<b>Prime Healthcare</b> Saving hospitals. Saving jobs. Saving lives.	100.0%	-	-	
Nov-24	B L A C K H I L L S SURGICAL HOSPITAL	USA	<b>Sanford Health</b> , nonprofit health system, acquired <b>Black Hills Surgical Hospital</b> , physician-owned surgical facility in Rapid City, South Dakota	SANF SRD	mfc MEDICAL FACILITIES CORPORATION	100.0%	\$194.0	-	

Source: Capital IQ, Companies' Press Releases, Mergermarket















## Hospitals – Q4 Global Transactions (2/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Nov-24	8 Skilled nursing facilities in Pennsylvania	USA	<b>PACS Group</b> , holding company investing in post-acute healthcare facilities, acquired <b>8</b> skilled nursing facilities in Pennsylvania, totaling 1,199 beds	<b>PACS</b>	-	100.0%	-	-	
Oct-24	11 Skilled Nursing Facilities in Tennessee	USA	<b>PACS Group</b> , holding company investing in post-acute healthcare facilities, acquired <b>11</b> <b>skilled nursing facilities in Tennessee</b> , totaling 1,310 beds	<b>PACS</b>	-	100.0%	-	-	
Oct-24	<b>31 Skilled Nursing</b> Facilities	USA	<b>CareTrust REIT</b> , real estate investment trust specializing in healthcare properties, acquired <b>31 skilled nursing facilities</b> totaling 3,290 licensed beds in Tennessee and Alabama, expanding its portfolio	CARETRUST	-	100.0%	\$500.0	-	
Oct-24	11 Nursing Home Properties in France	FRA	<b>Parkway Life REIT</b> , Asia's healthcare real estate investment trust, acquired <b>11 nursing</b> <b>home properties in France</b> , from DomusVi Group, European aged care provider	ParkwayLife REIT		100.0%	\$120.2	-	
Oct-24	<b>3 Urgent Medcare</b> Facilities	USA	<b>American Family Care (AFC)</b> , provider of urgent care, primary care, and occupational medicine, acquired <b>3 Urgent Medcare locations</b> from CRH Healthcare	<b>URGENT CARE</b> american family care	CRH HEALTHCARE Get in. Get out. Get better.	100.0%	-	-	
Oct-24 <sup>*</sup>	8 Healthcare Facilities in Missouri	USA	<b>Strawberry Fields REIT</b> , real estate investment trust specializing in healthcare properties, agreed to acquire <b>8 healthcare facilities in Missouri</b> , expanding its geographical footprint with a strong local operator	STRAWBERRY	-	100.0%	\$87.5	-	
Oct-24	Heartology Cardiovascular Hospital	IDN	<b>PT Astra Sehat Nusantara</b> , subsidiary of Astra International, acquired <b>Heartology</b> <b>Cardiovascular Hospital</b> , private cardiac center	PT Astra Sehat Nusantara	-	100.0%	\$41.3	-	
Oct-24	San Antonio Rehabilitation Hospital	USA	Methodist Healthcare System of San Antonio, healthcare provider, acquired San Antonio Rehabilitation Hospital, 48-bed inpatient facility, from NewEra IFR Holdings		New Ero	100.0%	-	-	
Oct-24	ORRMC Odessa Regional Medical Center Scenic Mountain Medical Center	USA	<b>Quorum Health</b> , operator of acute care hospitals and outpatient services, acquired <b>Odessa Regional Medical Center and Scenic Mountain Medical Center</b> , from Steward Health Care	<b>Q</b> QUORUM HEALTH	® Steward Steward Faith Care System	100.0%	-	-	
*Announc <b>ND:</b> Not D		ipproval an	d other closing conditions				Mean Median	13.9x 13.9x	

Source: Capital IQ, Companies' Press Releases, Mergermarket

















-



## Drug Stores - Q4 Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Dec-24	Wadsworth Medical Arts Pharmacy	USA	MGA Homecare, provider of physical and behavioral health services, acquired Wadsworth Medical Arts Pharmacy, pharmacy that offers prescriptions, compounded medications, and homecare supplies	HOMECARE <sup>M</sup>	-	100.0%	-	-	
Nov-24	MCMAHAN PHARMACY	USA	<b>CCMC Health System</b> , healthcare provider operating a 25-bed critical access hospital and multiple clinics, acquired <b>McMahan Pharmacy</b> , pharmacy in Texas	CCCCC Comanche County Medical Center Health System	-	100.0%	-	-	
Nov-24	<b>TotalCare</b> RX	USA	<b>Ray Anam Inc.</b> , consulting firm, acquired <b>Total Care Pharmacy</b> , provider of specialty, retail and long-term care pharmacy services	Ray Anam Inc.	-	100.0%	-	-	
Nov-24	Two EverCare Pharmacy locations	USA	<b>OneroRx</b> , provider of pharmacy and telepharmacy services, acquired <b>two EverCare</b> <b>Pharmacy locations in Princeton and Trenton</b> , expanding its presence to 67 locations across seven states		-	100.0%	-	-	
Oct-24	میدلیــــات زهـــرة الروضــة ZAHRAT ALRAWDAH	SAU	<b>BinDawood Holding Company</b> , retail conglomerate, acquired <b>Zahrat Al Rawdah</b> <b>Pharmacies LLC</b> , chain of 173 retail pharmacy outlets in Saudi Arabia, from Gulf Pharmaceutical Industries	<b>بن داود Bin Bin Pawood</b> Holding القابضة	PLANET	100.0%	\$118.2	-	
Oct-24	Cape Pharmacy	USA	<b>Beebe Healthcare</b> , nonprofit health system, acquired <b>Cape Pharmacy</b> , community- based pharmacy in Sussex County	<b>Beebe</b> Healthcare	-	100.0%	-	-	
Oct-24	50,000 sq. ft. facility in St. Louis, MO	USA	<b>Strive Compounding Pharmacy</b> , pharmacy specializing in personalized medications, acquired a <b>50,000 sq. ft. facility in St. Louis, MO</b> , aiming to enhance telehealth compounding and fulfillment services		-	100.0%	-	-	
Oct-24	Evans Pharmacy Services	GBR	<b>Raylane</b> , regional pharmacy chain, acquired <b>Evans Pharmacy</b> , pharmacy in Worcestershire, increasing its portfolio to 10 branches	Reylane	-	100.0%	-	_	
Oct-24	Bluegrass Drug Store	USA	<b>Ephraim McDowell Health</b> , healthcare provider, acquired <b>Bluegrass Drug Store</b> , community pharmacy, rebranding it as Ephraim McDowell Bluegrass Drug Store to enhance patient-centered care	Ephraim McDowell Regional Medical Center	_	100.0%	-	-	

\*Announced transactions pending approval and other closing conditions ND: Not Disclosed

Source: Capital IQ, Companies' Press Releases, Mergermarket







-

# 

#### TARGET Sensi-Care and Aloe Vesta

#### **TRANSACTION TYPE** Sell-side Advisory

#### INDUSTRIES

Healthcare, Personal Care

#### GEOGRAPHY Reading, GBR

#### **SITUATION**

Seale & Associates acted as financial advisor to ConvaTec Group (LON: CTEC) on the divesture of Sensi-Care and Aloe Vesta to Medline Industries. ConvaTec Group (LON: CTEC), is a global medical products company based in the United Kingdom.

#### **SEALE & ASSOCIATES' APPROACH**

Seale managed a competitive auction process with potential strategic and financial buyers for Sensi-Care and Aloe Vesta. Seale's disciplined approach allowed our client to maintain momentum, negotiating leverage throughout the process and ensure closing at a premium value and more favorable terms.

#### OUTCOME

The process resulted in a successful acquisition of Sensi-Care and Aloe Vesta by Medline Industries, a healthcare company with almost USD\$14 billion in annual sales. The divestiture is part of ConvaTec's strategy to focus on its core businesses and markets.

#### HEALTHCARE Q4 2024



"Seale was instrumental in keeping the process moving in a swift, orderly fashion"



"Seale was instrumental in keeping the process moving in a swift, orderly fashion. Their common sense and ability to find simple, common ground solutions while preserving our interests were invaluable in bringing this project to a successful conclusion."

George Landau, Vice President of Corporate **Development** at ConvaTec

# 

#### TARGET Laboratorios Portugal S.R.L

#### **TRANSACTION TYPE** Acquisition Advisory

#### INDUSTRIES

Healthcare, Pharmaceutical

#### GEOGRAPHY Peru

#### **SITUATION**

Seale & Associates acted as exclusive financial advisor to Invekra, assisting with comprehensive research on the Peruvian pharmaceutical market and the prioritization of potential acquisition targets.

#### **SEALE & ASSOCIATES' APPROACH**

Seale completed a thorough screening of the potential universe of pharmaceutical companies that would align with Invekra's strategy. Seale pre-qualified each potential target and initiated transaction discussions with the targets that best fit Invekra's strategy and investment criteria.

#### OUTCOME

The process resulted in a successful acquisition of Laboratorios Portugal S.R.L by Invekra, a conglomerate of 12 Latin American pharmaceutical companies. The acquisition strengthens Invekra's presence in Latin America.

#### HEALTHCARE Q4 2024

**"This acquisition strengthens** Invekra's presence in one of the fastest growing markets in Latin America"



"This acquisition strengthens Invekra's presence in one of the fastest growing markets in Latin America."

Carlos Hernández Goudet, Managing Director at Seale & Associates

## Sign up for M&A insights

We deliver sector-specific intelligence designed specifically for industry leaders, private equity firms, and their advisors. Our industry reports and featured articles deliver real-time access to key industry data, including:



#### Emerging industry trends

Quarterly reports covering 30+ industries Monthly reports for the U.S., Mexico, and Colombia

Transaction analysis and market trends

Valuable insights for industry leaders

#### Receive email updates with our proprietary data, reports, and insights as they are published for the industries that matter to you the most

SUBSCRIBE







## **Global M&A Representative Engagements**







#### **JAMES A. SEALE**

President and Founder | Washington, DC



32+ years of global M&A experience, Attorney, CPA Arthur Andersen, and Professor of Global Investment Banking at George Washington University University of Virginia - JD University of Kentucky - BS in Accounting



#### SERGIO GARCIA DEL BOSQUE

Managing Director | Mexico City, Mexico



+52 (55) 8000-7463

16+ years of global M&A experience IPADE - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering



#### **CARLOS HERNANDEZ GOUDET**


Managing Director | San Luis Potosi, Mexico



15+ years of global M&A experience Columbia University - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering







Please contact us if you would like further information about M&A trends and/or specific transaction multiples for your industry. © Seale & Associates



#### **BRETT M. CARMEL**

Senior Managing Director and Co-founder | Miami, FL

+1 (703) 294-6530 

25+ years of global M&A experience and Professor of M&A at Johns Hopkins University

The George Washington University - MBA International Business and MA - International Affairs

University of Florida - BA in Political Science with High Honors



#### **ROBERT E. WHITNEY**

Managing Director | Washington, DC

+1 (703) 801-8939

19+ years of global M&A experience, CPA Deloitte & Touche, Corporate Audit and Assurance Services University of Richmond - BS Business Administration in Accounting



#### **FELIPE BUENO**

Senior Director | Monterrey, Mexico



+52 (84) 4432-4444

32+ years with Grupo Industrial Saltillo with experience as Director, Corp. Dev. and extensive global commercial experience Instituto Tecnologico y de Estudios Superiores de Monterrey MBA and BS in Industrial Engineering







For over 25 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings



+\$50B

Closed Transactions Globally

## **Trusted Advisor to Leading Companies Worldwide**

We have worked repeatedly with many of the most well-known and respected companies in the world...



#### Services & Solutions

Mergers & Acquisitions Divestitures Joint Ventures / Alliances Recapitalizations Due Diligence / Support Expert Witness Testimony Corporate Finance Advisory Strategy Consulting

...as well as with many private equity funds, familyoffices and privately held companies.





# Seale & Associates Creative Solutions. Trusted Advice.

